Meeting
2022 ASCO Annual Meeting
Patients' preferences for adjuvant osimertinib in non–small cell lung cancer (NSCLC) after complete surgical resection: What makes it worth it to patients? (PATT)—The Roswell Park (RP) Comprehensive Cancer Center experience.
Authors
Angel Mier-Hicks
Roswell Park Comprehensive Cancer Center, New York, NY
Angel Mier-Hicks , Kristopher Attwood , Kayla Catalfamo , Prantesh Jain , Hongbin Chen , Edwin Yau , Amy P. Early , Grace K. Dy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8520)
DOI
10.1200/JCO.2022.40.16_suppl.8520
Abstract #
8520
Poster Bd #
147
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clinical and financial implications of ADUARA trial on a real-world population.
First Author: Bharathi Muthusamy
Poster
2023 ASCO Annual Meeting
Differential expression analysis of circRUNX1 in patients with early resected EGFR-mutant NSCLC.
First Author: Carlos Pedraz
Poster
2022 ASCO Annual Meeting
Neoadjuvant and adjuvant capmatinib in resectable non–small cell lung cancer with MET exon 14 skipping mutation or high MET amplification: GEOMETRY-N trial.
First Author: Jay M. Lee
Poster
2021 ASCO Annual Meeting
Cost evaluation of adjunctive osimertinib use in resected epidermal growth factor receptor-positive non-small cell lung cancer.
First Author: Briana Choi